Stephen E. Girardin

Stephen E. Girardin

Auto-generated profile, based on publicly available information

Stephen E. Girardin

Department of Immunology, University of Toronto, Toronto, Canada

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2008 in Immunity
Verified
Journal Article
Closed access
JTJenny P.-Y. Ting
Jenny P.-Y. Ting
RLRuth Caroline Lovering
Ruth Caroline Lovering
EAEmad S. Alnemri
Emad S. Alnemri
JBJohn Bertin
John Bertin
JBJeremy M. Boss
Jeremy M. Boss
Peter A WardPeter A Ward
Peter A Ward

4 August 2005 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
Jörg Hermann FritzJörg Hermann Fritz
Jörg Hermann Fritz
SGStephen E. Girardin
Stephen E. Girardin
CFCatherine Fitting
Catherine Fitting
CWCatherine Werts
Catherine Werts
DMDominique Mengin-Lecreulx
Dominique Mengin-Lecreulx
MAMinou Adib-Conquy
Minou Adib-Conquy
Muropeptides are degradation products of bacterial peptidoglycan (PG) sensed by nucleotide‐binding oligomerization domain 1 (NOD1) and NOD2, members of a recently discovered family of pattern recognition molecules (PRM). One of these muropeptides, muramyl dipeptide (MDP) mediates cell signaling by NOD2, exerts adjuvant activity and synergizes with lipopolysaccharide (LPS) to induce pro‐inflammatory responses in vitro and in vivo. In contrast, few and contradictory results exist about the stimulatory capacity of NOD1 agonists. Thus, the ability of NOD1 (MurNAc‐L‐Ala‐γ‐D‐Glu‐meso‐diaminopimelic acid, MtriDAP) and NOD2 (MurNAc‐L‐Ala‐D‐isoGln, MDP; MurNAc‐L‐Ala‐γ‐D‐Glu‐L‐Lys, MtriLYS) agonists to activate primary human myeloid cells was examined. We show that both CD14+ monocytes and CD1a+ immature dendritic cells (DC) express NOD1 and NOD2 mRNA. Stimulation of primary human monocytes and DC with highly purified muropeptides (MtriDAP, MDP and MtriLYS) induces release of pro‐inflammatory cytokines. We reveal here that NOD1 as well as NOD2 agonists act cooperatively with LPS to stimulate the release of both pro‐ and anti‐inflammatory cytokines in these myeloid cell subsets. Finally, we report that NOD1 as well as NOD2 agonists synergize with sub‐active doses of LPS to induce DC maturation, demonstrating that NOD agonists act cooperatively with molecules sensed by Toll‐like receptor 4 to instruct the onset of adaptive immune responses.

25 January 2008 in EMBO Reports
Verified
Journal Article
Open access
PDF file
ITIvan Tattoli
Ivan Tattoli
LCLeticia A Carneiro
Leticia A Carneiro
MJMuguette Jéhanno
Muguette Jéhanno
JMJoao G Magalhaes
Joao G Magalhaes
YSYoumin Shu
Youmin Shu
SGStephen E Girardin
Stephen E Girardin
NOD‐like receptors (NLRs) are a family of intracellular sensors of microbial‐ or danger‐associated molecular patterns. Here, we report the identification of NLRX1, which is a new member of the NLR family that localizes to the mitochondria. NLRX1 alone failed to trigger most of the common signalling pathways, including nuclear factor‐κB (NF)‐κB‐ and type I interferon‐dependent cascades, but could potently trigger the generation of reactive oxygen species (ROS). Importantly, NLRX1 synergistically potentiated ROS production induced by tumour necrosis factor α, Shigella infection and double‐stranded RNA, resulting in amplified NF‐κB‐dependent and JUN amino‐terminal kinases‐dependent signalling. Together, these results identify NLRX1 as a NLR that contributes to the link between ROS generation at the mitochondria and innate immune responses.

29 July 2011 in EMBO Reports
Verified
Journal Article
Open access
PDF file
DADamien Arnoult
Damien Arnoult
FSFraser Soares
Fraser Soares
ITIvan Tattoli
Ivan Tattoli
SGStephen E Girardin
Stephen E Girardin
Mitochondria are cellular organelles involved in host‐cell metabolic processes and the control of programmed cell death. A direct link between mitochondria and innate immune signalling was first highlighted with the identification of MAVS—a crucial adaptor for RIGI‐like receptor signalling—as a mitochondria‐anchored protein. Recently, other innate immune molecules, such as NLRX1, TRAF6, NLRP3 and IRGM have been functionally associated with mitochondria. Furthermore, mitochondrial alarmins—such as mitochondrial DNA and formyl peptides—can be released by damaged mitochondria and trigger inflammation. Therefore, mitochondria emerge as a fundamental hub for innate immune signalling.

1 February 2011 in Cell Research
Verified
Journal Article
Closed access
MSMatthew T Sorbara
Matthew T Sorbara
SGStephen E Girardin
Stephen E Girardin

14 September 2020 in Journal of Cell Biology
Verified
Journal Article
Open access
PDF file
SKSamuel A. Killackey
Samuel A. Killackey
DPDana J. Philpott
Dana J. Philpott
SGStephen E. Girardin
Stephen E. Girardin
Mitophagy is an evolutionarily conserved process involving the autophagic targeting and clearance of mitochondria destined for removal. Recent insights into the complex nature of the overlapping pathways regulating mitophagy illustrate mitophagy’s essential role in maintaining the health of the mitochondrial network. In this review, we highlight recent studies that have changed the way mitophagy is understood, from initiation through lysosomal degradation. We outline the numerous mitophagic receptors and triggers, with a focus on basal and physiologically relevant cues, offering insight into why they lead to mitochondrial removal. We also explore how mitophagy maintains mitochondrial homeostasis at the organ and system levels and how a loss of mitophagy may play a role in a diverse group of diseases, including cardiovascular, metabolic, and neurodegenerative diseases. With disrupted mitophagy affecting such a wide array of physiological processes, a deeper understanding of how to modulate mitophagy could provide avenues for numerous therapies.